It can be concluded that, in order to draw firm conclusions, it is necessary for future prospective studies to include only one type of histology/grading (i.e., GBM patients only), one type of additional agent, and the MGMT promoter methylation status at the primary treatment and re-irradiation stage, as well as the validated neurotoxicity scoring. This evidence concerns the gene MGMT and glioblastoma.